MAK HILL Publications Research Journal of Medical Sciences

Research Article
doi: 10.36478/makrjms.2024.8.263.267

Alpha-Mangostin and Its Potential Therapeutic Applications: An Experimental Study

[1]Sana Shahzad and [2]Amir Alam

[1]*Department of Pharmacy, The University of Faisalabad*

[2]*Department of pharmacology, Lord Buddha Koshi Medical College and Hospital*

Abstract

Alpha-mangostin, a xanthone derivative isolated from the pericarp of the mangosteen fruit (Garcinia mangostana), has demonstrated a range of pharmacological activities in preclinical studies. This experimental study aims to investigate the therapeutic potential of alpha-mangostin in various disease models, focusing on its antioxidant, anti-inflammatory, anticancer, antimicrobial, and neuroprotective effects. This study employed in vitro and in vivo models to evaluate the pharmacological effects of alpha-mangostin. Antioxidant activity was assessed using DPPH and ABTS radical scavenging assays. Anti-inflammatory effects were evaluated using LPS-stimulated macrophages and measuring levels of pro-inflammatory cytokines. Anticancer activity was assessed in multiple cancer cell lines using MTT and apoptosis assays. Antimicrobial effects were tested against a panel of bacterial and fungal pathogens. Neuroprotective effects were studied in a mouse model of neurodegeneration induced by oxidative stress. Data were analyzed using appropriate statistical methods to determine the significance of the findings. Alpha-mangostin exhibited significant antioxidant activity, reducing DPPH and ABTS radicals in a dose-dependent manner. In LPS-stimulated macrophages, alpha-mangostin significantly decreased the production of pro-inflammatory cytokines TNF-a, IL-1ß, and IL-6. In cancer cell lines, alpha-mangostin induced apoptosis and inhibited cell proliferation in a dose-dependent manner. Alpha-mangostin also demonstrated potent antimicrobial activity against both Gram-positive and Gram-negative bacteria, as well as fungi. In the neurodegeneration model, alpha-mangostin treatment resulted in reduced oxidative stress and improved behavioral outcomes. Alpha-mangostin shows significant potential as a therapeutic agent due to its multi-faceted pharmacological properties. Its antioxidant, anti-inflammatory, anticancer, antimicrobial, and neuroprotective effects suggest potential applications in treating a variety of diseases. Further studies, including clinical trials, are warranted to confirm these findings and explore the therapeutic use of alpha-mangostin in humans.

OPEN ACCESS

Key Words

Alpha-mangostin, antioxidant, anti-inflammatory, anticancer, antimicrobial, neuroprotection, therapeutic potential

Corresponding Author

Sana Shahzad,
Department of Pharmacy The University of Faisalabad

Author Designation

[1]Assistant professor
[2]Professor

Received: 25 May 2024
Accepted: 17 July 2024
Published: 20 July 2024

Citation: Sana Shahzad and Amir Alam, 2024. Alpha-Mangostin and Its Potential Therapeutic Applications: An Experimental Study. Res. J. Med. Sci., 18: 263-267, doi: 10.36478/makrjms.2024.8.263.267

INTRODUCTION

Alpha-mangostin, a xanthone derivative, is a bioactive compound predominantly found in the pericarp of the mangosteen fruit (Garcinia mangostana). Historically valued for its medicinal properties in traditional medicine, alpha-mangostin has gained attention in modern pharmacological research due to its broad spectrum of biological activities[1,2]. This compound has been shown to exert potent antioxidant, anti-inflammatory, anticancer, antimicrobial and neuroprotective effects, making it a promising candidate for the development of new therapeutic agents[3].

Despite numerous in vitro and in vivo studies suggesting the potential health benefits of alpha-mangostin, there is a need for comprehensive experimental studies to evaluate its therapeutic efficacy across various disease models[4]. This study aims to fill this gap by systematically investigating the pharmacological effects of alpha-mangostin in a series of well-defined experimental settings[5-8]. By exploring its mechanisms of action and therapeutic potential, we aim to provide a foundation for future clinical research and drug development.

MATERIALS AND METHODS

This experimental study was designed to evaluate the therapeutic potential of alpha-mangostin using a variety of in vitro and in vivo models. The study was conducted in accordance with ethical guidelines and received approval from the Institutional Animal Care and Use Committee (IACUC) for the use of animals in research.

Study Design: The study involved a series of experiments to assess the antioxidant, anti-inflammatory, anticancer, antimicrobial and neuroprotective effects of alpha-mangostin. The compound was isolated from the pericarp of Garcinia mangostana and purified using standard chromatographic techniques.

Antioxidant Activity: Antioxidant activity was assessed using DPPH (2,2-diphenyl-1-picrylhydrazyl) and ABTS (2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)) radical scavenging assays. Alpha-mangostin was tested at various concentrations (1, 5, 10, 25, 50 µM) to determine its radical scavenging ability. The IC50 values (concentration required to inhibit 50% of the radicals) were calculated[9].

Anti-Inflammatory Effects: The anti-inflammatory effects of alpha-mangostin were evaluated using lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophages. Cells were treated with different concentrations of alpha-mangostin (1, 5, 10, 25 µM), and the levels of pro-inflammatory cytokines (TNF-a, IL-1ß and IL-6) were measured using ELISA kits[5].

Anticancer Activity: The anticancer activity of alpha-mangostin was assessed in multiple human cancer cell lines, including MCF-7 (breast cancer), A549 (lung cancer) and HeLa (cervical cancer). Cell viability was measured using the MTT assay and apoptosis was evaluated by flow cytometry after staining with annexin V-FITC and propidium iodide[6].

Antimicrobial Effects: The antimicrobial activity of alpha-mangostin was tested against a panel of bacterial (Staphylococcus aureus, Escherichia coli) and fungal (Candida albicans, Aspergillus niger) pathogens. Minimum inhibitory concentrations (MICs) were determined using the broth microdilution method[5,10].

Neuroprotective Effects: The neuroprotective effects of alpha-mangostin were studied in a mouse model of oxidative stress-induced neurodegeneration. Mice were treated with alpha-mangostin (10, 25, 50 mg/kg) for 14 days, and oxidative stress markers (malondialdehyde, MDA., superoxide dismutase, SOD) and behavioral outcomes (Y-maze test) were assessed[6,8].

Statistical Analysis: Data were analyzed using GraphPad Prism software. Results were expressed as mean±SD. Statistical significance was determined using one-way ANOVA followed by Tukey's post hoc test for multiple comparisons. A $p<0.05$ was considered statistically significant.

RESULTS AND DISCUSSIONS

The results section includes detailed findings from the various experimental models used to evaluate the therapeutic potential of alpha-mangostin.

This table presents the antioxidant activity of alpha-mangostin, demonstrating its effectiveness in scavenging DPPH and ABTS radicals in a dose-dependent manner.

This table shows the reduction in pro-inflammatory cytokine levels (TNF-a, IL-1ß, and IL-6) in LPS-stimulated macrophages treated with different concentrations of alpha-mangostin, indicating its anti-inflammatory effects.

This table presents the effects of alpha-mangostin on cell viability and apoptosis in various human cancer cell lines (MCF-7, A549, HeLa). The results indicate a dose-dependent decrease in cell viability and an increase in apoptosis.

This table shows the minimum inhibitory concentrations (MICs) of alpha-mangostin against different bacterial and fungal pathogens, indicating its broad-spectrum antimicrobial activity.

Table 1: Antioxidant Activity

Concentration (µM)	DPPH Radical Scavenging (%)	ABTS Radical Scavenging (%)
1	10 ± 2	12 ± 3
5	30 ± 5	35 ± 4
10	55 ± 6	60 ± 5
25	75 ± 7	78 ± 6
50	90 ± 5	92 ± 4
IC50 (µM)	8.5	8.0

Table 2: Anti-Inflammatory Effects

Concentration (µM)	TNF-a (pg/mL)	IL-1ß (pg/mL)	IL-6 (pg/mL)
Control	200 ± 20	150 ± 15	180 ± 18
1	180 ± 18	140 ± 14	170 ± 17
5	150 ± 15	120 ± 12	140 ± 14
10	100 ± 10	80 ± 8	90 ± 9
25	50 ± 5	40 ± 4	50 ± 5

Table 3: Anticancer Activity

Cell Line	Concentration (µM)	Cell Viability (%)	Apoptosis (%)
MCF-7	Control	100	5 ± 1
	5	85 ± 5	10 ± 2
	10	70 ± 5	20 ± 3
	25	50 ± 4	35 ± 4
	50	30 ± 3	50 ± 5
A549	Control	100	4 ± 1
	5	80 ± 4	12 ± 2
	10	65 ± 5	25 ± 3
	25	45 ± 3	40 ± 4
	50	25 ± 2	55 ± 5
HeLa	Control	100	6 ± 1
	5	75 ± 5	15 ± 2
	10	60 ± 5	30 ± 3
	25	40 ± 4	45 ± 4
	50	20 ± 2	60 ± 5

Table 4: Antimicrobial Activity

Pathogen	MIC (µg/mL)
Staphylococcus aureus	8
Escherichia coli	16
Candida albicans	12
Aspergillus niger	10

Table 5: Neuroprotective Effects

Treatment Group	MDA (nmol/mg protein)	SOD (U/mg protein)	Y-Maze Spontaneous Alternation (%)
Control	20 ± 2	50 ± 5	55 ± 5
Alpha-Mangostin 10 mg/kg	15 ± 1	60 ± 4	65 ± 6
Alpha-Mangostin 25 mg/kg	12 ± 1	70 ± 5	70 ± 5
Alpha-Mangostin 50 mg/kg	10 ± 1	80 ± 6	75 ± 6

This table presents the effects of alpha-mangostin on oxidative stress markers (MDA and SOD) and cognitive performance (Y-maze spontaneous alternation) in a mouse model of neurodegeneration, indicating its neuroprotective effects.

The findings of this experimental study demonstrate the significant therapeutic potential of alpha-mangostin across various disease models. Alpha-mangostin exhibited potent antioxidant, anti-inflammatory, anticancer, antimicrobial, and neuroprotective activities, supporting its use as a multi-functional therapeutic agent[11].

Antioxidant Activity: Alpha-mangostin demonstrated strong antioxidant activity in both DPPH and ABTS radical scavenging assays. The IC50 values were comparable to those of standard antioxidants, indicating its potential to mitigate oxidative stress-related damage in various diseases. The ability of alpha-mangostin to neutralize free radicals suggests its application in conditions characterized by oxidative stress, such as cardiovascular diseases, neurodegenerative disorders, and cancer[12].

Anti-Inflammatory Effects: The anti-inflammatory effects of alpha-mangostin were evident from the significant reduction in pro-inflammatory cytokines (TNF-a, IL-1ß and IL-6) in LPS-stimulated macrophages. This anti-inflammatory property can be attributed to its ability to modulate key signaling pathways involved in inflammation, such as NF-κB and MAPK pathways. These findings highlight the potential of alpha-mangostin in treating inflammatory diseases, including arthritis, inflammatory bowel disease, and psoriasis[13].

Anticancer Activity: In various human cancer cell lines, alpha-mangostin effectively inhibited cell viability and induced apoptosis in a dose-dependent manner. The compound's ability to trigger apoptosis through mitochondrial and extrinsic pathways, along with its effects on cell cycle regulation, underscores its

potential as an anticancer agent. These results suggest that alpha-mangostin could be developed as a complementary therapy in cancer treatment, targeting multiple pathways involved in tumor growth and survival[6,11].

Antimicrobial Activity: Alpha-mangostin exhibited broad-spectrum antimicrobial activity against both bacterial and fungal pathogens. The MIC values indicate that alpha-mangostin is effective at inhibiting the growth of common pathogens, suggesting its potential use as an antimicrobial agent. This could be particularly beneficial in developing new treatments for antibiotic-resistant infections and for use in topical applications to prevent or treat skin infections[2].

Neuroprotective Effects: The neuroprotective effects of alpha-mangostin were demonstrated in a mouse model of oxidative stress-induced neurodegeneration. Treatment with alpha-mangostin resulted in reduced oxidative stress markers (MDA) and increased antioxidant enzyme activity (SOD), along with improved cognitive performance in the Y-maze test. These findings support the potential of alpha-mangostin in preventing or slowing the progression of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease[4,14].

Clinical Implications: The diverse pharmacological activities of alpha-mangostin suggest its potential as a versatile therapeutic agent. Its antioxidant and anti-inflammatory properties could be beneficial in managing chronic diseases characterized by oxidative stress and inflammation. The anticancer and antimicrobial activities indicate potential applications in oncology and infectious diseases, respectively. Furthermore, the neuroprotective effects open new avenues for the treatment of neurodegenerative disorders.

Future Directions: While the preclinical results are promising, further research is needed to translate these findings into clinical applications. Future studies should focus on optimizing the formulation and delivery of alpha-mangostin to enhance its bioavailability and therapeutic efficacy. Clinical trials are essential to evaluate the safety, tolerability and effectiveness of alpha-mangostin in humans. Additionally, investigating the molecular mechanisms underlying its pharmacological effects will provide deeper insights into its therapeutic potential.

CONCLUSION

This experimental study highlights the significant therapeutic potential of alpha-mangostin, demonstrating its efficacy in various in vitro and in vivo models. The compound's antioxidant, anti-inflammatory, anticancer, antimicrobial, and neuroprotective effects suggest its application in a wide range of diseases. Alpha-mangostin represents a promising candidate for the development of new therapeutic agents, and further research is warranted to explore its clinical potential.

By integrating the findings from this study into future research and clinical practice, healthcare providers can leverage the benefits of alpha-mangostin to improve patient outcomes across multiple disease areas. The journey from bench to bedside will involve rigorous clinical testing and validation, but the therapeutic promise of alpha-mangostin makes it worth the effort. The promising results from this study provide a strong foundation for further investigation into the therapeutic applications of alpha-mangostin.

REFERENCES

1. You, Y., J. Xu, Y. Liu, H. Li and L. Xie et al., 2023. Tailored apoptotic vesicle delivery platform for inflammatory regulation and tissue repair to ameliorate ischemic stroke. ACS Nano, 17: 8646-8662.
2. Alam, M., S. Rashid, K. Fatima, M. Adnan and A. Shafie et al., 2023. Biochemical features and therapeutic potential of a-mangostin: Mechanism of action, medicinal values, and health benefits. Bio. amp Pha., Vol. 163 .10.1016/j.biopha. 2023.114710.
3. Yang, A., C. Liu, J. Wu, X. Kou and R. Shen, 2021. A review on a-mangostin as a potential multi-target-directed ligand for alzheimer's disease. Eur. J. Phar., Vol. 897 .10.1016/j.ejphar. 2021.173950.
4. Sakpakdeejaroen, I., P. Muanrit, S. Panthong and S. Ruangnoo, 2022. Alpha-mangostin-loaded transferrin-conjugated lipid-polymer hybrid nanoparticles: Development and characterization for tumor-targeted delivery. Sci. World J., Vol. 2022 .10.1155/2022/9217268.
5. Do, H.T.T. and J. Cho, 2020. Mangosteen pericarp and its bioactive xanthones: Potential therapeutic value in alzheimer's disease, parkinson's disease, and depression with pharmacokinetic and safety profiles. Int. J. Mol. Sci., Vol. 21 .10.3390/ijms21176211.
6. Santhi, V.P., P. Masilamani, V. Sriramavaratharajan, R. Murugan and S.S. Gurav *et al*., 2021. Therapeutic potential of phytoconstituents of edible fruits in combating emerging viral infections. J. Food Bio., Vol. 45, No. 8 .10.1111/jfbc.13851.
7. Chin, G.S., H. Todo, W.R. Kadhum, M.A. Hamid and K. Sugibayashi, 2016. In Vitro Permeation and Skin Retention of a-MangostinProniosome. Che amp Pha Bull., 64: 1666-1673.

8. Oka, N., V.T.H. Doan, H. Matsubara, T. Imai and Y. Yoshioka et al., 2023. Protective effects of alpha-mangostin encapsulated in cyclodextrin-nanoparticle on cerebral ischemia. J. Con Re., 353: 216-228.
9. Fang, Y., C. Yang, Z. Yu, X. Li, Q. Mu, G. Liao and B. Yu, 2020. Natural products as lsd1 inhibitors for cancer therapy. Acta Phar Sin B., 11: 621-631.
10. Usman, F., H.S. Shah, S. Zaib, S. Manee and J. Mudassir et al., 2021. Fabrication and biological assessment of antidiabetic a-mangostin loaded nanosponges: in vitro, in vivo, and in silico studies. Molecules, Vol. 26, No. 21 .10.3390/molecules 26216633.
11. Chen, Y.L., Y.C. Chen, L.A. Xiong, Q.Y. Huang and T.T. Gong et al., 2023. Discovery of phenylcarbamoyl xanthone derivatives as potent neuroprotective agents for treating ischemic stroke. Eur. J. Medic. Chem., Vol. 251 .10.1016/ j.ejmech.2023.115251.
12. Qu, S., Y. Han, Y. Liu, J. Zhu, U. Acaroz, J. Shen and K. Zhu, 2022. Milk exosomes facilitate oral delivery of drugs against intestinal bacterial infections. J. Agric. Food Chem., Vol. 70, No. 51 .10.1021/ acs.jafc.2c04971.
13. Wu, L., Q. Li, J. Deng, J. Shen and W. Xu et al., 2021. Platelet-tumor cell hybrid membrane-camouflaged nanoparticles for enhancing therapy efficacy in glioma. Int. J. Nan., 16: 8433-8446.